Correspondence

Somapacitan, lonapegsomatropin and somatrogon: ACMD advice

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.

• From: Advisory Council on the Misuse of Drugs
• Published: 13 August 2025
• Last updated: 23 February 2026 — See all updates

Documents

ACMD advice on somapacitan, lonapegsomatropin and somatrogon (accessible)

HTML

ACMD advice on somapacitan, lonapegsomatropin and somatrogon

PDF, 141 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Somapacitan, lonapegsomatropin and somatrogon have been granted a marketing authorisation in the UK. This letter provides advice on their classification and scheduling.

Read the government response to the 3 ACMD reports on medicines.

Published 13 August 2025

Last updated 23 February 2026 + show all updates

1. 23 February 2026

   Added link to government response.

2. 13 August 2025

   First published.